Want to see COSM full AI Analyst Report?
COSM Stock Chart & Stats
$0.20
<$0.01(3.75%)
At close: 4:00 PM EDT
$0.20
<$0.01(3.75%)
Day’s Range― - ―
52-Week Range$0.16 - $1.32
Previous Close$0.2
Volume2.90M
Average Volume (3M)16.84M
Market Cap
$12.42M
Enterprise Value$31.22
Total Cash (Recent Filing)$548.93K
Total Debt (Recent Filing)$17.42M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Aug 24, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding62,078,396
10 Day Avg. Volume6,443,995
30 Day Avg. Volume16,844,547
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)$87.30M
Bulls Say, Bears Say
Bulls Say
Robust Revenue GrowthTTM revenue expansion (~$69.5M) and ~29.8% reported revenue growth indicate durable demand for Cosmos’s distribution channels. Sustained top-line growth supports scale economies, broader customer relationships with pharmacies/wholesalers, and a pathway to spread fixed costs over larger volumes.
Improved Leverage; Positive EquityLeverage materially improved versus 2025 and equity remains positive (~$19.8M), reducing near-term solvency risk. A lower debt-to-equity ratio eases interest burden and gives management more flexibility to finance operations or strategic initiatives without immediate refinancing pressure.
Expanded Financing & Incentive ToolsShareholder approval of an omnibus equity plan and Series B preferred authorization creates lasting financing and compensation flexibility. These tools help attract/retain talent, permit structured capital raises, and provide strategic optionality to support growth or balance-sheet management.
Bears Say
Consistently Negative ProfitabilityThin gross margins and persistent negative operating/net margins show the business model currently fails to convert sales into sustainable profits. Continued losses erode returns, limit reinvestment capacity, and challenge the long-term viability unless cost structure or mix improves.
Chronic Cash BurnNegative operating and free cash flow indicate the company consumes cash rather than funds its operations, increasing reliance on external financing. Over a multi-month horizon this constrains strategic options, heightens execution risk, and raises the probability of capital raises if cash burn persists.
Dilution And Financing RiskWhile new authorizations provide flexibility, they also raise the likelihood of equity or preferred issuance to cover cash needs. Given ongoing losses and cash burn, the company may rely on dilutive financings, which can weaken per-share economics and long-term shareholder value.
Cosmos Holdings News
COSM FAQ
What was Cosmos Holdings’s price range in the past 12 months?
Cosmos Holdings lowest stock price was $0.16 and its highest was $1.32 in the past 12 months.
What is Cosmos Holdings’s market cap?
Cosmos Holdings’s market cap is $12.42M.
When is Cosmos Holdings’s upcoming earnings report date?
Cosmos Holdings’s upcoming earnings report date is Aug 24, 2026 which is in 23 days.
How were Cosmos Holdings’s earnings last quarter?
Currently, no data Available
Is Cosmos Holdings overvalued?
According to Wall Street analysts Cosmos Holdings’s price is currently Overvalued.
Does Cosmos Holdings pay dividends?
Cosmos Holdings does not currently pay dividends.
What is Cosmos Holdings’s EPS estimate?
Cosmos Holdings’s EPS estimate is 0.01.
How many shares outstanding does Cosmos Holdings have?
Cosmos Holdings has 62,078,396 shares outstanding.
What happened to Cosmos Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cosmos Holdings?
Currently, no hedge funds are holding shares in COSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cosmos Holdings
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Technical Analysis
Ownership Overview
28.14% Insiders
0.49% Mutual Funds
<0.01% Other Institutional Investors
71.09% Public Companies and
Individual Investors